137 related articles for article (PubMed ID: 22361042)
1. The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) program in practice: does it really inform patients and limit risk?
Cohen RA; Brown RS
Am J Kidney Dis; 2012 May; 59(5):604-6. PubMed ID: 22361042
[No Abstract] [Full Text] [Related]
2. Message to the FDA on ESAs: REMS is not enough, more studies are needed.
Singh AK
Clin J Am Soc Nephrol; 2010 Aug; 5(8):1355-8. PubMed ID: 20688885
[No Abstract] [Full Text] [Related]
3. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.
Winkelmayer WC
J Am Soc Nephrol; 2011 Jan; 22(1):1-2. PubMed ID: 21164031
[No Abstract] [Full Text] [Related]
4. Understanding risk evaluation and mitigation strategies in organ transplantation.
Gabardi S
Pharmacotherapy; 2011 Jul; 31(7):714-22. PubMed ID: 21923459
[TBL] [Abstract][Full Text] [Related]
5. Full results on risks of epoetin emerge 14 years after major dialysis study.
Epstein K
BMJ; 2012 May; 344():e3535. PubMed ID: 22619221
[No Abstract] [Full Text] [Related]
6. Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management.
Peppin JF; Coleman JJ; Kirsh KL
Issues Law Med; 2011; 27(2):91-119. PubMed ID: 22372206
[TBL] [Abstract][Full Text] [Related]
7. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
Singh AK
Clin J Am Soc Nephrol; 2010 Apr; 5(4):553-6. PubMed ID: 20203166
[No Abstract] [Full Text] [Related]
8. FDA finalizes REMS program for ESAs; Amgen continues to study risks.
Brower V
J Natl Cancer Inst; 2010 May; 102(9):592-3. PubMed ID: 20421565
[No Abstract] [Full Text] [Related]
9. Evolving regulatory landscape with erythropoiesis-stimulating agents and impact on managed care.
Fatodu H
Am J Manag Care; 2010 Mar; 16 Suppl Issues():S74-9. PubMed ID: 20297875
[TBL] [Abstract][Full Text] [Related]
10. Food and Drug Administration's Safe Use Initiative collaborating to reduce preventable harm from medications.
U S Food And Drug Administration
J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):76-93. PubMed ID: 20345207
[No Abstract] [Full Text] [Related]
11. The Food and Drug Administration risk evaluation and mitigation strategy.
Craig DS
J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):145-8. PubMed ID: 20504137
[TBL] [Abstract][Full Text] [Related]
12. New limits advised for anemia drugs.
Mitka M
JAMA; 2007 Jun; 297(22):2464. PubMed ID: 17565074
[No Abstract] [Full Text] [Related]
13. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA).
Krapf R; Hulter HN
Clin J Am Soc Nephrol; 2009 Feb; 4(2):470-80. PubMed ID: 19218474
[TBL] [Abstract][Full Text] [Related]
14. The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program - Current Status and Future Direction.
Wu J; Juhaeri J
Clin Ther; 2016 Dec; 38(12):2526-2532. PubMed ID: 27914632
[TBL] [Abstract][Full Text] [Related]
15. Opioid risk management: understanding FDA mandated risk evaluation and mitigation strategies (REMS).
Sloan PA
J Opioid Manag; 2009; 5(3):131-3. PubMed ID: 19662921
[No Abstract] [Full Text] [Related]
16. Use of erythropoietins in patients with renal transplants.
Treleaven DJ; Clase CM
BMJ; 2009 Oct; 339():b3825. PubMed ID: 19854838
[No Abstract] [Full Text] [Related]
17. The Food and Drug Administration opioid Risk Evaluation and Mitigation Strategy.
Lipman AG
J Pain Palliat Care Pharmacother; 2009; 23(3):219-21. PubMed ID: 19670017
[No Abstract] [Full Text] [Related]
18. Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education.
Nicholson SC; Evanyo K; Salinas GD; Roepke N; Burton BS; Susalka D
J Opioid Manag; 2012; 8(4):212-6. PubMed ID: 22941848
[TBL] [Abstract][Full Text] [Related]
19. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
Wright C; Schnoll S; Bernstein D
Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
[TBL] [Abstract][Full Text] [Related]
20. Shared risk evaluation mitigation strategy for all immediate-release transmucosal fentanyl dosage forms.
Food And Drug Administration, Public Health Service, U.S. Department Of Health And Human Services
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):123-6. PubMed ID: 22764848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
